

EXHIBIT C

<b>Company Name</b>	<b>Symbol</b>	<b>Date 1</b>	<b>Price 1</b>	<b>Date 2</b>	<b>Price 2</b>	<b>% Drop</b>
<b>Keryx Biopharmaceuticals, Inc.</b>	<b>KERX</b>	03/07/08	\$ 5.26	03/10/08	\$ 0.64	87.83%
Keryx said the Phase III clinical trial failed to meet the primary objective of the study (key diabetes drug candidate Sulonex)						
<b>Sonus Pharmaceuticals Inc.</b>	<b>SNUS</b>	09/21/07	\$ 4.35	09/24/07	\$ 0.70	83.91%
Sonus Pharmaceuticals Inc. SNUS:SONUS Pharmaceuticals Inc said Monday that its Phase 3 trial of Tocosol Paclitaxel in women with metastatic breast cancer did not meet its primary endpoint						
<b>Renovis, Inc.</b>	<b>RNVS</b>	10/25/06	\$ 14.20	10/26/06	\$ 3.43	75.85%
announcement of the failure of a phase 3 trial for drug candidate NXY-059, which had blockbuster potential to treat certain types of strokes. Partner Renovis (Nasdaq: RNVS) was crushed on the news, falling more than 70%						
<b>Genitope Corporation</b>	<b>GTOP</b>	12/20/07	\$ 2.59	12/21/07	\$ 0.82	68.34%
Genitope said a Phase III trial examining the use of MyVax in previously untreated patients with follicular B-cell non-Hodgkin's lymphoma did not meet the primary target.						
<b>Columbia Laboratories, Inc.</b>	<b>CBRX</b>	02/02/07	\$ 4.61	02/05/07	\$ 1.48	67.90%
Columbia Laboratories' progesterone gel for the prevention of preterm birth in women with a previous preterm birth earlier than 35-weeks gestation failed in its Phase III trial. Prochieve did not achieve any reduction in the incidence of preterm birth at						
<b>Panacos Pharmaceuticals, Inc.</b>	<b>PANC</b>	11/17/03	\$ 2.25	11/18/03	\$ 0.75	66.67%
In addition, on November 17, 2003, Vitex announced that it received a recommendation on that date from an independent Data Safety Monitoring Committee ("DSMC") to halt enrollment in its Phase III chronic trial of the INACTINE™ Pathogen Reduction System f						
<b>Cadence Pharmaceuticals, Inc.</b>	<b>CADX</b>	01/10/08	\$ 13.99	01/11/08	\$ 5.36	61.69%
Cadence Pharmaceuticals, Inc. (Nasdaq: CADX - News) today announced top line results of two of the company's four pivotal, Phase III clinical trials of Acetavance(TM), a formulation of acetaminophen for intravenous use. One of these clinical trials did no						
<b>AtheroGenics, Inc.</b>	<b>AGIX</b>	03/16/07	\$ 7.83	03/19/07	\$ 3.09	60.54%
AtheroGenics, Inc. (NasdaqGM:AGIX - News) today announced that its ARISE Phase III clinical study of its lead drug candidate, AGI-1067, did not show a difference from placebo in its composite primary endpoint; however,						
<b>DepoMed, Inc.</b>	<b>DEPO</b>	07/09/07	\$ 4.93	07/10/07	\$ 2.00	59.43%
DepoMed(DEPO - Cramer's Take - Stockpickr) shares nosedived Tuesday after the specialty pharmaceutical company announced that a phase III clinical trial for Gabapentin didn't meet its primary endpoint.						
<b>SciClone Pharmaceuticals, Inc.</b>	<b>SCLN</b>	12/13/05	\$ 3.85	12/14/05	\$ 2.31	40.00%
Shares of SciClone Pharmaceuticals Inc. plunged Wednesday, after Phase III trial data for the company's drug to treat hepatitis C liver disease showed no significant benefit to its patients.						

<b>Average % Drop</b>	<b>67.21%</b>
-----------------------	---------------